ReviewBritish journal of pharmacology2023
Ca
Review in British journal of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Inhibition of CaV1.4 channels by CaV3 channel antagonists ML218 and Z944.The Journal of general physiology · 2026Article
- Sclareol and cinnarizine are non-selective inhibitors of voltage-gated Cav1.3 L-type CaChannels (Austin, Tex.) · 2025Article
- Article
- Mitochondrial Glutamine Metabolism Drives Epileptogenesis in Primary Hippocampal Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Advancing age and sex modulate antidyskinetic efficacy of striatal CaNeurobiology of aging · 2025Article
- Altered Protein Kinase A-Dependent Phosphorylation of Cav1.2 in Left Ventricular Myocardium fromInternational journal of molecular sciences · 2024Article
- Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Novel protocol for multiple-dose oral administration of the L-type CaChannels (Austin, Tex.) · 2024Article
- The L-type calcium channel CaV1.3: A potential target for cancer therapy.Journal of cellular and molecular medicine · 2024Review
- Selective blockade of CaNature communications · 2024Article
- CaBritish journal of pharmacology · 2023Review
- Design and Applications of Genetically-Encoded Voltage-Dependent Calcium Channel Inhibitors.Handbook of experimental pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Voltage-gated L-type Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.